Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.66
+0.10 (1.52%)
Mar 31, 2025, 12:46 PM EDT - Market open
Coya Therapeutics Revenue
In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%. Coya Therapeutics had revenue of $1.95K in the quarter ending December 31, 2024, a decrease of -99.97%.
Revenue (ttm)
$3.55M
Revenue Growth
-40.79%
P/S Ratio
28.13
Revenue / Employee
$444,258
Employees
8
Market Cap
111.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
COYA News
- 5 days ago - Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Business Wire
- 13 days ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
- 4 weeks ago - Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations - Business Wire
- 7 weeks ago - Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD - Seeking Alpha
- 7 weeks ago - Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha
- 7 weeks ago - Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing - Benzinga
- 7 weeks ago - Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development - Business Wire
- 7 weeks ago - Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire